193
Participants
Start Date
January 31, 2009
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
Quetiapine XR
Oral treatment with 150 up to 300 mg/day once daily in the evening
Placebo
Oral treatment once daily in the evening
Research Site, Dothan
Research Site, Scottsdale
Research Site, Little Rock
Research Site, Escondido
Research Site, Bradenton
Research Site, Gainsville
Research Site, North Miami
Research Site, Tampa
Research Site, Atlanta
Research Site, Smyrna
Research Site, Eagle
Research Site, Hoffman Estates
Research Site, Terre Haute
Research Site, Overland Park
Research Site, Wichita
Research Site, Clinton Township
Research Site, Minneapolis
Research Site, Flowood
Research Site, St Louis
Research Site, Lincoln
Research Site, Rochester
Research Site, Cincinnati
Research Site, Cleveland
Research Site, Mason
Research Site, Oklahoma City
Research Site, Charleston
Research Site, Memphis
Research Site, Wharton
Research Site, Virginia Beach
Research Site, Bothell
Research Site, Milwaukee
Research Site, Bogota D.c
Research Site, Bello
Research Site, Bogotá
Research Site, Medellín
Research Site, Vijaywada
Research Site, Ahmedabad
Research Site, Vadodara
Research Site, Varanasi
Research Site, León
Research Site, Monterrey
Research Site, Belgrade
Research Site, Novi Sad
Research Site, Pretoria
Research Site, Cape Town
Research Site, Taoyuan District
Research Site, Changhua
Research Site, Taipei
Lead Sponsor
AstraZeneca
INDUSTRY